Evidence map›Paper›PMID 36900382›Full record

ArticleCancers2023

Transgenic HA-1-Specific CD8

Artem Pilunov, Dmitrii S Romaniuk, Anton Shmelev, Savely Sheetikov, Anna N Gabashvili, Alexandra Khmelevskaya, Dmitry Dianov, Ksenia Zornikova, Naina T Shakirova, Murad Vagida and 2 more

Full text read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Artem PilunovNational Hematology Research Center, 125167 Moscow, Russia.
Dmitrii S RomaniukNational Hematology Research Center, 125167 Moscow, Russia.
Anton ShmelevNational Hematology Research Center, 125167 Moscow, Russia.
Savely SheetikovNational Hematology Research Center, 125167 Moscow, Russia.
Anna N GabashviliNational Hematology Research Center, 125167 Moscow, Russia.ORCID 0000-0002-4251-3002
Alexandra KhmelevskayaNational Hematology Research Center, 125167 Moscow, Russia.
Dmitry DianovNational Hematology Research Center, 125167 Moscow, Russia.
Ksenia ZornikovaNational Hematology Research Center, 125167 Moscow, Russia.
Naina T ShakirovaNational Hematology Research Center, 125167 Moscow, Russia.
Murad VagidaNational Hematology Research Center, 125167 Moscow, Russia.ORCID 0000-0001-7408-3994
Apollinariya BogolyubovaNational Hematology Research Center, 125167 Moscow, Russia.ORCID 0000-0002-8664-6341
Grigory A EfimovNational Hematology Research Center, 125167 Moscow, Russia.

Funding

Russian Foundation for Basic Research 19-29-04156
6 · The paper itself

Abstract

A significant share of allogeneic hematopoietic stem cell transplantations (allo-HSCT) results in the relapse of malignant disease. The T cell immune response to minor histocompatibility antigens (MiHAs) promotes a favorable graft-versus-leukemia response. The immunogenic MiHA HA-1 is a promising target for leukemia immunotherapy, as it is predominantly expressed in hematopoietic tissues and presented by the common HLA A*02:01 allele. Adoptive transfer of HA-1-specific modified CD8

Indexed as

acute myeloid leukemiaadoptive transferallo-HSCTHA-1minor histocompatibility antigenstransgenic TCR

Identifiers

PMID36900382
PMCPMC10000933

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read40
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.